XHS - ETF AI Analysis
Top Page
SPDR S&P Health Care Services ETF (XHS)
XHS, the SPDR S&P Health Care Services ETF, has a solid overall rating that reflects a mix of strong performers and some more challenged holdings in the health care services space. Leaders like CorVel, Cigna, and Hinge Health support the fund’s quality through strong financial performance, growth momentum, and positive earnings calls, while names such as AMN Healthcare and Concentra face operational and technical headwinds that likely weigh on the rating. The main risk factor is that many holdings share similar sector-specific issues like leverage, margin pressure, and occasional overvaluation, which can affect the ETF if conditions worsen across health care services companies.
XHS vs. SPDR S&P 500 ETF (SPY)
- AUM
- 223.72M
- Region
- North America
- Expense Ratio
- 0.35%
- Beta
- 0.58
- Issuer
- SPDR
- Inception Date
- Sep 28, 2011
- Dividend Yield
- 0.15%
- Asset Class
- Equity
- Index Tracked
- S&P Health Care Services Select Industry
XHS Summary
XHS is the SPDR S&P Health Care Services ETF, which follows the S&P Health Care Services Select Industry Index. It focuses on U.S. companies that provide medical care, such as hospitals, home health services, and specialty clinics. Holdings include well-known names like Tenet Healthcare and NeoGenomics. Someone might invest in XHS to gain diversified exposure to the health care services theme, which can benefit from an aging population and steady demand for medical care. A key risk is that health care stocks can still go up and down with the overall stock market and changes in health care regulations.
How much will it cost me?
This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 invested. That’s a bit higher than the cost of a typical broad, passively managed index ETF because this fund is more specialized, focusing on a specific slice of the health care sector.
What would affect this ETF?
Future performance of XHS could benefit from steady demand for U.S. health care services, an aging population, and ongoing medical innovation that supports providers like Option Care Health, McKesson, and Molina Healthcare. On the other hand, changes in government health care policy, reimbursement rates, and broader economic or interest rate shifts that pressure hospital and outpatient budgets could weigh on this ETF.
XHS Top 10 Holdings
XHS is firmly anchored in U.S. health care providers and services, with fast-growing names like Hinge Health, NeoGenomics, and Guardant Health doing much of the heavy lifting as their shares keep rising on strong growth stories despite profitability concerns. BillionToOne and Nutex Health add to the momentum, reflecting a bet on innovative, smaller players. On the flip side, Hims & Hers has been losing steam, and Clover Health’s mixed trajectory has introduced some drag. Overall, the fund is a concentrated play on U.S. health care services innovation rather than broad, defensive health care.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 OPCH | Option Care Health | 2.20% | $4.93M | $4.68B | 11.34% | 73Outperform |
 AMN | AMN Healthcare Services | 2.27% | $5.08M | $1.86B | 140.53% | 50Neutral |
 HNGE | Hinge Health, Inc. Class A | 2.00% | $4.48M | $9.00B | 125.07% | 70Outperform |
 CRVL | CorVel | 1.99% | $4.45M | $4.24B | 11.74% | 75Outperform |
 MCK | McKesson | 1.89% | $4.23M | $116.68B | 26.21% | 62Neutral |
 CON | Concentra Group Holdings Parent, Inc. | 1.95% | $4.36M | $5.01B | 91.00% | 66Neutral |
 MOH | Molina Healthcare | 1.86% | $4.16M | $10.92B | 29.91% | 71Outperform |
 PRVA | Privia Health Group | 1.87% | $4.17M | $2.86B | -13.41% | 71Outperform |
 USPH | US Physical Therapy | 1.90% | $4.24M | $1.32B | -3.08% | 63Neutral |
 ACHC | Acadia Healthcare | 1.88% | $4.21M | $2.93B | 34.09% | 61Neutral |
XHS Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XHS, the sentiment is Positive. The current price of 141.40 is above the 20-day moving average (MA) of 136.71, above the 50-day MA of 136.13, and above the 200-day MA of 120.40, indicating a bullish trend. The MACD of 1.66 indicates Negative momentum. The RSI at 61.59 is Neutral, neither overbought nor oversold. The STOCH value of 90.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XHS.
XHS Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| XHS | $141.40 | $148.00(4.67% Upside) | $223.72M | 0.35% | 65Neutral |
 RSPH | $39.44 | $42.00(6.48% Upside) | $972.11M | 0.40% | 71Outperform |
 PJP | $125.03 | $156.08(24.83% Upside) | $565.40M | 0.58% | 70Neutral |
 XPH | $62.70 | $108.48(73.01% Upside) | $450.42M | 0.35% | 57Neutral |
 PBE | $98.72 | $124.15(25.76% Upside) | $432.18M | 0.59% | 70Outperform |
 PINK | $39.64 | $49.65(25.25% Upside) | $328.02M | 0.51% | 65Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| XHS | SPDR S&P Health Care Services ETF | 141.40 | 35.98 | 34.14% | |
| RSPH | Invesco S&P 500 Equal Weight Health Care ETF | 39.44 | 8.79 | 28.69% | |
| PJP | Invesco Dynamic Pharmaceuticals ETF | 125.03 | 30.71 | 32.56% | |
| XPH | SPDR S&P Pharmaceuticals ETF | 62.70 | 13.82 | 28.28% | |
| PBE | Invesco Dynamic Biotechnology & Genome ETF | 98.72 | 26.06 | 35.86% | |
| PINK | Simplify Health Care ETF | 39.64 | 6.65 | 20.15% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.